16-30 of 872
Exploring Patient Perspectives on Genetic Testing for ATTR-CM
On the Frontlines of ATTR-CMExploring Patient Perspectives on Genetic Testing for ATTR-CM
Precision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
CardiologyPrecision Medicine in Obstructive HCM Care: The Promise of Cardiac Myosin Inhibitors
The Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe Lp(a)-Lowering Landscape: Navigating Current and Future Therapeutic Options
DARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
CardiologyDARE AF Trial: Dapagliflozin to Reduce AF Burden After Catheter Ablation in Patients Without Diabetes or Heart Failure
DECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
CardiologyDECAF Trial: Does Eliminating Coffee Reduce Atrial Fibrillation Recurrence in Symptomatic Patients?
POLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
CardiologyPOLY HF Trial: A Polypill Strategy for Heart Failure With Reduced Ejection Fraction (HFrEF)
- advertisement
The LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
CardiologyThe LDL-C-Lowering Landscape: Navigating Current and Future Therapeutic Options
ADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
CardiologyADAPT AF-DES: Antithrombotic Strategies Beyond 12 Months for Patients With AF Treated With Drug-Eluting-Stents
OCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
CardiologyOCEAN Trial at AHA 2025: Anticoagulation After AF Ablation in High-Risk Patients
Primary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
CardiologyPrimary Results of the VESALIUS-CV Trial: Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke
Real-World Impact of Evolocumab on MACE Reduction in ASCVD
CardiologyReal-World Impact of Evolocumab on MACE Reduction in ASCVD
Global Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
CardiologyGlobal Burden of Stroke and Myocardial Infarction in Patients at High Risk of First MACE: Insights From the VESALIUS-REAL Study
- advertisement
Evolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
CardiologyEvolocumab in Patients at High Cardiovascular Risk Without Prior MI or Stroke: Primary Results of the VESALIUS-CV Trial
Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
